LATANOPROST; NETARSUDIL DIMESYLATE - Generic Drug Details

What are the generic sources for latanoprost; netarsudil dimesylate and what is the scope of patent protection?

Latanoprost; netarsudil dimesylate is the generic ingredient in one branded drug marketed by Alcon Labs Inc and is included in one NDA. There are seventeen patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Latanoprost; netarsudil dimesylate has sixty-eight patent family members in fourteen countries.

One supplier is listed for this compound.

Summary for LATANOPROST; NETARSUDIL DIMESYLATE

International Patents:	68
US Patents:	17
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LATANOPROST; NETARSUDIL DIMESYLATE
DailyMed Link:	LATANOPROST; NETARSUDIL DIMESYLATE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for LATANOPROST; NETARSUDIL DIMESYLATE

Constraining patent/regulatory exclusivity:

11,185,538

Dosage:

SOLUTION/DROPS;OPHTHALMIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for LATANOPROST; NETARSUDIL DIMESYLATE

Drug Class	Rho Kinase Inhibitor
Mechanism of Action	Rho Kinase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for LATANOPROST; NETARSUDIL DIMESYLATE

S01EE	Prostaglandin analogues
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

S01EX	Other antiglaucoma preparations
S01E	ANTIGLAUCOMA PREPARATIONS AND MIOTICS
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for LATANOPROST; NETARSUDIL DIMESYLATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ROCKLATAN	Ophthalmic Solution	latanoprost; netarsudil dimesylate	0.005%/0.02%	208259	2	2021-12-20

US Patents and Regulatory Information for LATANOPROST; NETARSUDIL DIMESYLATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes	10,174,017		Y	Y
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes	10,532,993
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes	9,931,336		Y	Y
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes	10,588,901		Y	Y
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes	11,020,385

International Patents for LATANOPROST; NETARSUDIL DIMESYLATE

Country	Patent Number	Title	Estimated Expiration
Canada	2929545
Canada	2731869	COMPOSES AMIDES BETA ET GAMMA-AMINO ISOQUINOLINE ET COMPOSES BENZAMIDE SUBSTITUE (BETA-AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS)
Japan	2016053060	疾患の治療のための二重機構阻害剤 (DUAL MECHANISM INHIBITOR FOR TREATMENT OF DISEASE)
European Patent Office	2424857
Australia	2016201754	Dual mechanism inhibitors for the treatment of disease

Supplementary Protection Certificates for LATANOPROST; NETARSUDIL DIMESYLATE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3053913	122020000016	Germany		PRODUCT NAME: NETARSUDIL, ODER EIN ENANTIOMER, DIASTEREOMER, SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/19/1400 20191119
3053913	C202030018	Spain		PRODUCT NAME: NETARSUDIL O UN ENANTIOMERO, DIASTEREOMERO, SAL O SOLVATO DEL MISMO.; NATIONAL AUTHORISATION NUMBER: EU/1/19/1400; DATE OF AUTHORISATION: 20191119; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1400; DATE OF FIRST AUTHORISATION IN EEA: 20191119
3053913	301038	Netherlands		PRODUCT NAME: NETARSUDIL, OF EEN ZOUT OF SOLVAAAT DAARVAN, IN HET BIJZONDER NETARSUDILMESYLAAT; REGISTRATION NO/DATE: EU/1/19/1400 20191121
3053913	20C1017	France		PRODUCT NAME: NETARSUDIL, OU ENANTIOMERE, DIASTEREOMERE, SEL OU SOLVATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/19/1400 20191121
3461484	2021C/515	Belgium		PRODUCT NAME: ROCLANDA - LATANOPROST / NETARSUDIL; AUTHORISATION NUMBER AND DATE: EU/1/20/1502 20210108

Latanoprost / Netarsudil Dimesylate: Market Dynamics and Financial Trajectory

Last updated: May 9, 2026

What product scope does the market cover?

“Latanoprost; Netarsudil dimesylate” is a fixed-dose combination built from:

• Latanoprost (prostaglandin analog; aqueous humor outflow)
• Netarsudil dimesylate (ROCK inhibitor and NET inhibitor; reduces resistance at the trabecular meshwork)

The commercial market is defined by topical ophthalmic glaucoma and ocular hypertension use patterns, where payer, channel, and persistence dynamics are driven by:

• chronic indication conversion (new patients shift to drops based on efficacy and tolerability)
• formulary positioning for prostaglandin analog backbones
• competition from other Rho-kinase inhibitors and prostaglandin combinations

How is pricing and reimbursement likely to behave in this class?

Pricing in glaucoma is dominated by:

1. Class anchor pricing around prostaglandin analogs (latanoprost) that sets the “ceiling” for add-on therapy.
2. Add-on premium tied to incremental efficacy and tolerability for the second agent (netarsudil).
3. Formulary leverage that pushes toward preferred agents and restricts non-preferred coverage after step edits or prior authorization.

In practice, the combo’s financial trajectory tends to follow the reimbursement path of the netarsudil component, not the older latanoprost backbone, because the prostaglandin base is often widely covered and price-pressured.

What market dynamics determine adoption of this combination?

Key adoption drivers in topical glaucoma include:

• Efficacy-to-side-effect trade-off: ROCK inhibitor regimens face utilization friction from corneal/ocular surface tolerability and patient comfort. That dynamic governs conversion from monotherapy prostaglandin analogs and sustains or limits share expansion.
• Dosing persistence: chronic drop use depends on tolerability and regimen simplicity. Fixed combination formatting can raise persistence relative to separate agents, if it reduces burden and dosing errors.
• Switching behavior in ophthalmology: clinicians tend to switch based on IOP reduction needs and tolerability, then hold if target pressures are met. This means penetration accelerates quickly in unmet-IOP segments and then slows as the market saturates among controlled patients.
• Channel concentration: sales are concentrated in large ophthalmology providers, specialty pharmacies, and long-tail retail pharmacy patterns for chronic refills. Specialty distribution is more common for newer add-ons with coverage constraints.
• Competition cycles: new entrants in ROCK inhibition, combination drops, and adjunctive pathways shift prescriber choice. Share tends to rotate based on formulary access, patient response, and adverse event profile.

Where does this combination compete?

The competitive set in glaucoma typically clusters by mechanism and formulary status:

• Prostaglandin analog monotherapy (latanoprost and alternatives)
• Prostaglandin plus add-on combinations (especially second agents that improve IOP more than prostaglandin alone)
• ROCK inhibitors as monotherapy or in combos (netarsudil-centered competitors and later-generation equivalents)
• Other outflow modulators (adenosine pathway agents, adrenergic pathways, carbonic anhydrase inhibitors, and fixed-combination regimens)

The netarsudil component is the differentiator; the prostaglandin component is the volume anchor.

What financial trajectory is typical for fixed-dose glaucoma combos with netarsudil?

Netarsudil-driven financial trajectories in ophthalmology generally follow a pattern:

• Early adoption phase: limited payer access and tolerability-driven switching reduce volume velocity.
• Expansion phase: improved formulary access and prescriber familiarity support share gains, mostly in patients inadequately controlled on prostaglandin monotherapy.
• Plateau/pressure phase: as the market saturates controlled patients and payers tighten preferences, growth stabilizes and new competitive entrants compress pricing or share.

In business terms, the combo’s financial path typically hinges on:

• whether it becomes a preferred formulary option for second-line therapy
• whether persistence remains high enough to convert patients from “trial then switch” behavior
• whether competitive launches coincide with sustained payer restriction cycles

What are the value chain economics that shape revenue?

Ophthalmic glaucoma economics are affected by three levers:

1) Pricing and net-to-gross

Net sales depend on:

• payer rebates and chargebacks (often meaningful in ophthalmics with channel concentration)
• patient assistance and co-pay coverage for chronic use
• contract pricing to large accounts and distributor terms

For a combo containing a newer component (netarsudil), rebates can rise when formulary access is contested, which limits margin expansion even when revenue grows.

2) Volume from line-of-therapy transitions

Revenue scales with:

• conversion from prostaglandin monotherapy to combo therapy when IOP remains above target
• conversion from inadequate response to alternative add-on regimens

If netarsudil tolerability limits persistence, the combo’s net volume growth slows even with initial uptake.

3) Share stability vs competitive entries

Share is sensitive to:

• clinical protocol changes at large provider groups
• payer formularies that shift preferred status between similar mechanism options
• launch timing of competing fixed-dose glaucoma drops

What risks most likely compress long-term financial performance?

1. Formulary exclusion or tier downshifts for netarsudil-containing regimens.
2. Tolerability or real-world persistence gaps that lead to switching after initial use.
3. Competitive efficacy claims that shift prescriber preference, especially if adverse event profiles appear more favorable.
4. Pricing pressure from generic prostaglandin backbones that reduce willingness to pay for combos unless incremental benefit is clear.
5. Regulatory or label-change dynamics (if they occur) that affect patient eligibility or prescriber confidence.

What upside factors can extend growth duration?

1. Stable preferred coverage in key commercial plans for second-line glaucoma treatment.
2. Clinical positioning that supports netarsudil combo use before switching to alternate classes.
3. Better persistence outcomes in practice than expected from early trials.
4. Channel expansion that reduces pharmacy friction and improves refill continuity.

How can investors map this to a financial model?

A practical revenue model for this combo should structure demand around:

• Diagnosed glaucoma population treated with topical therapy
• Share of patients above target IOP on prostaglandin monotherapy (serviceable available market for “add-on conversion”)
• Probability of staying on therapy through at least 6 to 12 months (persistence-adjusted conversion)
• Payer mix shift over time (commercial vs Medicare; preferred vs non-preferred access)
• Realized net pricing after rebates and discounts

A typical model shape is:

• front-loaded uptake in second-line patient segments
• then a curve flattening if persistence and formulary access stop improving
• re-acceleration only if coverage broadens or competition weakens

What key near-term market signals drive quarterly results?

For this class, quarterly momentum is usually dominated by:

• TRx growth (new starts and refills) rather than list price
• Net-to-gross stability based on payer contract cycles
• Channel inventory dynamics at ophthalmic distributors and specialty pharmacies
• Formulary status changes tied to plan renewals

Because this is a chronic product, results typically move with refill persistence and contract renewals.

What does the trajectory look like versus the broader glaucoma market?

Broad glaucoma market growth is supported by aging demographics and ongoing diagnosis. The combo’s outperformance depends on whether it captures second-line switchers from prostaglandin monotherapy and retains them.

When netarsudil combos do well, they:

• win a meaningful portion of the “inadequate control” segment
• maintain persistence that produces durable refill demand
• avoid major reimbursement setbacks

When they underperform, revenue stalls because:

• most patients either stay on prostaglandin monotherapy or switch to competing add-ons
• tolerability leads to early discontinuation
• payer restrictions cap volume even when prescribers want access

Key Takeaways

• Market demand is line-of-therapy driven: growth depends on converting prostaglandin monotherapy patients to add-on therapy and sustaining refill persistence.
• Financial trajectory is netarsudil-led: list price matters less than payer access, rebates, and persistence.
• Main upside requires preferred coverage and durable tolerability: formulary status and real-world persistence determine whether the adoption curve keeps rising or plateaus.
• Main downside is switching and tiering risk: adverse event-driven discontinuation and payer tier-downs compress TRx and net pricing.
• Model revenues around persistence-adjusted conversion: translate diagnosed glaucoma treated with drops into second-line add-on demand with persistence and payer mix adjustments.

FAQs

1) What drives adoption of latanoprost plus netarsudil dimesylate?

Conversion of patients with uncontrolled IOP on prostaglandin analogs, tempered by tolerability and refill persistence.

2) What is the biggest determinant of net sales growth for this combo?

TRx growth that reflects both new starts and sustained refills under payer coverage conditions.

3) How does formulary status affect financial performance?

Preferred-tier placement increases volume and reduces effective discounting pressure; tier downshifts cap access and widen rebate intensity.

4) Does list price or realized net pricing matter more?

Realized net pricing matters more because rebate and contract dynamics can offset list price changes.

5) What competitive forces most threaten share?

New fixed-dose glaucoma drops and alternative add-ons that gain formulary preferences and preserve persistence with comparable or better efficacy.

---

References

[1] FDA. “Netarsudil” and “Latanoprost” product labeling and regulatory materials (accessed via FDA Drugs@FDA).
[2] FDA. “Combining glaucoma therapies” and drug safety communications relevant to topical ocular hypotensive agents (FDA safety and labeling pages).
[3] Center for Medicare & Medicaid Services (CMS). National coverage policy context for ocular drugs and Part D formulary considerations (CMS drug coverage guidance).
[4] IQVIA and other market research providers’ published glaucoma utilization and TRx trends (publicly reported industry summaries).